AstraZeneca PLC logged a -2.4% change during today's morning session, and is now trading at a price of $69.45 per share. The ...

IPO fundraising in the U.K. market fell to at least a 30-year low in the first half of this year, according to data from ...

In early corporate news, AstraZeneca receives EU approval for a bladder cancer therapy, and a subdued housing market leaves MJ Gleeson eyeing adjusted pretax profit at the lower end of current market ...